8-K current report · filed Aug 6, 2026

TriSalus Life Sciences, Inc. (TLSI) 8-K Current Report: August 6, 2026

Item 2.02Item EX-99.1TLSI overview

Short answer

TriSalus Life Sciences, Inc. (TLSI) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial results released for quarter ended June 30, 2026.

TriSalus Life Sciences, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q2 2026 financial results released for quarter ended June 30, 2026
  • Full operating metrics and management commentary contained in Exhibit 99.1
  • Exhibit 99.1 furnished under Item 2.02, limiting Section 18 Exchange Act liability absent specific incorporation reference

Item EX-99.1 · Exhibit EX-99.1

  • Q2 revenue $11.4M, up 1.7% year over year, signaling modest commercial growth despite expanded sales investment
  • Gross margin improved to 86.8% from 83.9%, supported by lower TriNav unit costs
  • Operating loss widened to $9.8M from $7.3M as sales and marketing expense rose to $11.4M
  • Cash $46.3M after $46.0M gross Q1 equity proceeds, funding commercial expansion and pipeline development
  • 2026 revenue guidance maintained at $54M to $57M, representing expected growth of 19% to 26%

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other TriSalus Life Sciences, Inc. 8-K filings

Get the next TLSI 8-K as it lands

Follow TLSI for push alerts, or ask the research agent what this filing means.